“As of the end of the quarter, we had $268 million remaining under our current share repurchase program, which we expect to complete by the end of the year.”

In context

“iven by declines in MSP volumes, partially offset by the growth of on!. When adjusted for calendar differences and trade inventory movements, segment volumes declined by an estimated 2% and 2.5% for the third quarter and first nine months, respectively. Oral Tobacco Products Segment retail share declined 4.2 percentage points in the third quarter as declines in our MSP brands were partially offset by the year-over-year growth of on!. Turning to capital allocation. We continue to return significant cash to shareholders. In the third quarter, we paid approximately $1.6 billion in dividends and raised our dividend by 4.3% in August, in line with our new progressive dividend goal. This increase marked our 58th increase in the last 54 years, and repurchased 5.9 million shares for $260 million. As of the end of the quarter, we had $268 million remaining under our current share repurchase program, which we expect to complete by the end of the year. In addition, our balance sheet remained strong through the quarter. As of the end of the third quarter, our debt to EBITDA ratio was 2.1 times. Let's turn to our financial outlook for the remainder of the year. We are narrowing our full year 2023 guidance range and now expect to deliver diluted -- adjusted diluted earnings per share in a range of $4.91 to $4.98. This range represents a growth rate of 1.5% to 3% from a base of $4.84 in 2022. Finally, at our Investor Day, we announced the creation of our connect and transform open innovation system, which is focused on partnering externally to leverage subject matter expertise, new technologies and disruptive innovations to augment our internal capabilities and support our innovation strategies. As part of this system, today we are publishi”